

Response to reviewers' comments

Association of Hidradenitis Suppurativa with Crohn's Disease. Meng Zhang, et al. The following questions should be solved:

Q1: Would move ADM as treatment out of etio/patho to treatment

Reply: Thanks for your comments. We have moved adalimumab from etio/patho to treatment. All modifications have been highlighted in yellow.

-Clinical features – Q2: Could be more detailed and should, at least, mention axilla. Would delve more into clinical course.

Reply: Thank you. The more detailed clinical features of HS have been supplied in the context with highlighted yellow color in the "Clinical features" part.

-Treatment – Q3: First paragraph needs rewording and should provide more details. would expand this section. "hormonal" not harmonic.

Reply: Great thanks for your comments. We have exchanged the harmonic into hormonal. In addition, we have made some adjustments in the first paragraph, which have been highlighted in yellow.

Q4: Need to add references i.e. smoking and obesity.

Reply: Great thanks. The related references of smoking and obesity have been added.

Q5: Need more data from trials on biologics, particularly ADM. Antibiotics + other therapies? Data on tnfr+IMM? Data on immunomodulators or other agents?

Reply: Thanks for your comments. We have provided the reported results of clinical trials according to literature. All modifications have been highlighted in yellow. We are more inclined to describe how to treat Crohn's disease combined with hidradenitis suppurativa, but there are few relevant studies,

and we cannot find more reliable data to prove the effectiveness of other drugs such as antibiotics and immune preparations.

- Conclusion - Q5: Not sure case really adds anything. After photo without prior photo (figure 6).

Reply: Thanks for your comments. Originally, that case was used to prove the effectiveness of Multimodal therapy, but unfortunately, there is no relevant preoperative and intraoperative pictures in this case. Based on your opinion, I have replaced another case to prove the efficacy.

Q6: Conclusion section provides data that was not previously discussed (2nd paragraph)

Reply: Thanks for your comments. The relevant content has been modified in the section of clinical features with highlighted yellow color.